martes, 1 de septiembre de 2020

Clinical benefit of immune checkpoint inhibitors approved by US Food and Drug Administration | BMC Cancer | Full Text

Clinical benefit of immune checkpoint inhibitors approved by US Food and Drug Administration | BMC Cancer | Full Text

We describe the clinical benefit of immune checkpoint inhibitors using the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS) and ASCO VF.
Authors:Fei Liang, Sheng Zhang, Qin Wang and Wenfeng Li
Citation:BMC Cancer 2020 20:823
Content type:Research article
 
Published on: 

No hay comentarios:

Publicar un comentario